Modest weight loss of 5% to 10% among patients who are overweight or obese can result in a clinically relevant reduction in cardiovascular (CV) disease risk.1 This amount of weight loss can increase insulin sensitivity in adipose tissue, liver, and muscle, and have a positive impact on blood sugar, blood pressure, triglycerides, and high-density lipoprotein cholesterol.1,2

All patients who are obese or overweight with increased CV risk should be counseled on diet, exercise, and other behavioral interventions.3 Weight loss secondary to lifestyle modification alone, however, leads to adaptive physiologic responses, which increase appetite and reduce energy expenditure.4–6

Pharmacotherapy can counteract this metabolic adaptation and lead to sustained weight loss. Antiobesity medication can be considered if a patient has a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with obesity-related comorbidities such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.3,7

Until recently, there were few pharmacologic options approved by the US Food and Drug Administration (FDA) for the management of obesity. The mainstays of treatment were phentermine (Adipex-P, Ionamin, Suprenza) and orlistat (Alli, Xenical). Since 2012, however, 4 agents have been approved as adjuncts to a reduced-calorie diet and increased physical activity for long-term weight management.8,9 Phentermine/topiramate extended-release (ER) (Qsymia) and lorcaserin (Belviq) were approved in 2012,10,11 and naltrexone sustained release (SR)/bupropion SR (Contrave) and liraglutide 3 mg (Saxenda) were approved in 201412,13 (TABLE). These medications have the potential to not only limit weight

**Practice recommendations**

For patients with a body mass index (BMI) ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities:
- Consider antiobesity pharmacotherapy when diet, exercise, and behavior modification do not produce sufficient weight loss. A
- Continue an antiobesity medication if it is deemed effective and well tolerated. A

**Strength of recommendation:**
A Good-quality patient-oriented evidence  
B Inconsistent or limited-quality patient-oriented evidence  
C Consensus, usual practice, opinion, disease-oriented evidence, case series

---

Katherine H. Saunders, MD; Alpana P. Shukla, MD, MRCP; Leon I. Igel, MD; and Louis J. Aronne, MD

Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Cornell Medicine, New York, New York.

Drs. Saunders, Shukla, and Igel reported no potential conflicts of interest relevant to this article. Dr. Aronne reported various financial relationships with Aspire Bariatrics, AstraZeneca, BMIQ, Eisai, Gelesis, GI Dynamics, Jamieson Laboratories, Janssen Pharmaceuticals, MYOS RENS Technology Inc., Novo Nordisk, Pfizer, Real Appeal, UnitedHealth Group Ventures, and Zafgen.

Despite the growing obesity epidemic and the availability of several additional medications for chronic weight management, use of antiobesity pharmacotherapy has been limited. Barriers to use include inadequate training of health care professionals, poor insurance coverage for new agents, and low reimbursement for office visits to address weight. In addition, the number of obesity medicine specialists, while increasing, is still not sufficient. Therefore, it is imperative for other health care professionals—including ObGyns—to be aware of the treatment options available to patients who are overweight.

### TABLE  Antiobesity medications: What to expect and who makes a good candidate

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism, dosage, and available formulations</th>
<th>Trial and duration</th>
<th>Trial arms</th>
<th>Weight loss (%)</th>
<th>Good candidates</th>
<th>Poor candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phentermine (Adipex-P, Ionamin, Lomaira, Suprenza)</td>
<td>Adrenergic agonist 8–37.5 mg/d Capsule, tablet</td>
<td>28 weeks</td>
<td>15 mg/d 7.5 mg/d Placebo (topiramate ER and phentermine/topiramate ER arms excluded)</td>
<td>6.06 5.45 1.71</td>
<td>Dry mouth, insomnia, dizziness, irritability</td>
<td>Younger patients who need assistance with appetite suppression</td>
</tr>
<tr>
<td>Orlistat (Alli, Xenical)</td>
<td>Lipase inhibitor 60–120 mg three times per day with meals Capsule</td>
<td>208 weeks</td>
<td>120 mg three times per day Placebo</td>
<td>9.6 (Week 52) 5.25 (Week 208) 5.61 (Week 52) 2.71 (Week 208)</td>
<td>Fecal urgency, oily stool, flatus with discharge, fecal incontinence</td>
<td>Patients with hypercholesterolemia and/or constipation who can limit their intake of dietary fat</td>
</tr>
<tr>
<td>Phentermine/topiramate ER (Qsymia)</td>
<td>Adrenergic agonist/neurostabilizer 3.75/23–15/92 mg/d Capsule</td>
<td>56 weeks</td>
<td>15/92 mg/d 3.75/23 mg/d Placebo</td>
<td>10.9 5.1 1.6</td>
<td>Paresthesias, dizziness, dysgeusia, insomnia, constipation, dry mouth</td>
<td>Younger patients who need assistance with appetite suppression</td>
</tr>
<tr>
<td>Orlistat (Alli, Xenical)</td>
<td>Lipase inhibitor 60–120 mg three times per day with meals Capsule</td>
<td>208 weeks</td>
<td>120 mg three times per day Placebo</td>
<td>9.6 (Week 52) 5.25 (Week 208) 5.61 (Week 52) 2.71 (Week 208)</td>
<td>Fecal urgency, oily stool, flatus with discharge, fecal incontinence</td>
<td>Patients with hypercholesterolemia and/or constipation who can limit their intake of dietary fat</td>
</tr>
</tbody>
</table>
## TABLE Antiobesity medications: What to expect and who makes a good candidate

(continued)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism, dosage, and available formulations</th>
<th>Trial and duration</th>
<th>Trial arms</th>
<th>Weight loss (%)</th>
<th>Most common adverse effects</th>
<th>Good candidates</th>
<th>Poor candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lorcaserin (Belviq, Belviq XR)²⁷</td>
<td>Serotonin 5-HT2C receptor agonist</td>
<td>BLOOM²⁸</td>
<td>10 mg twice per day</td>
<td>5.8⁺</td>
<td>Headache, dizziness, fatigue, nausea, dry mouth, constipation</td>
<td>Patients who report inadequate meal satiety</td>
<td>Patients on other serotonin modulating medications; patients with known cardiac valvular disease; patients who are pregnant</td>
</tr>
<tr>
<td></td>
<td>10 mg twice per day or 20 mg/d ER Tablet</td>
<td>52 weeks</td>
<td>Placebo</td>
<td>2.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BLOSSOM²³</td>
<td>52 weeks</td>
<td>10 mg twice per day</td>
<td>5.8⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 mg/d</td>
<td>4.7⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BLOOM-DM¹⁰</td>
<td>52 weeks</td>
<td>10 mg twice per day</td>
<td>4.5⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 mg/d</td>
<td>5.0⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naltrexone SR/bupropion SR (Contrave)³¹</td>
<td>Opioid receptor antagonist/ noradrenaline and norepinephrine reuptake inhibitor</td>
<td>COR-I²⁷</td>
<td>16/180 mg twice per day</td>
<td>6.1⁺</td>
<td>Nausea, vomiting, constipation, headache, dizziness, insomnia, dry mouth</td>
<td>Patients who describe cravings for food and/or addictive behaviors related to food; patients who are trying to quit smoking, reduce alcohol intake, and/or have comorbid depression</td>
<td>Patients with uncontrolled hypertension, uncontrolled pain, recent MAOI use, history of seizures, or any condition that predisposes to seizure such as anorexia/bulimia nervosa, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs; patients who are pregnant</td>
</tr>
<tr>
<td></td>
<td>16/180 mg twice per day</td>
<td>8/180 mg twice per day</td>
<td>Placebo</td>
<td>5.0⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COR-II³³</td>
<td>56 weeks</td>
<td>16/180 mg twice per day</td>
<td>6.4⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COR-BMOD³⁴</td>
<td>56 weeks</td>
<td>16/180 mg twice per day</td>
<td>9.3⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>5.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COR-DIABETES³⁵</td>
<td>56 weeks</td>
<td>16/180 mg twice per day</td>
<td>5.0⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>1.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide 3 mg (Saxenda)³⁰</td>
<td>GLP-1 receptor agonist</td>
<td>SCALE Obesity and Prediabetes²⁷</td>
<td>3 mg/d</td>
<td>8.0⁺</td>
<td>Nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain</td>
<td>Patients who report inadequate meal satiety, and/or have type 2 diabetes, prediabetes, or impaired glucose tolerance; patients requiring use of concomitant psychiatric medications</td>
<td>Patients with an aversion to needles, history of pancreatitis, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2; patients who are pregnant</td>
</tr>
<tr>
<td></td>
<td>0.6–3 mg/d</td>
<td>56 weeks</td>
<td>Placebo</td>
<td>2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prefilled pen for subcutaneous injection</td>
<td>SCALE Diabetes³⁸</td>
<td>3 mg/d</td>
<td>6⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>56 weeks</td>
<td>Placebo</td>
<td>4.7⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SCALE Maintenance³⁹</td>
<td>56 weeks</td>
<td>3 mg/d</td>
<td>6.2⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ER, extended release; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; LCD, low-calorie diet; MAOI, monoamine oxidase inhibitor; XR, extended release.

⁺P<.001 vs placebo.
Obesity: When to consider medication

CONTINUED FROM PAGE 43

or obese and to be adept at using them.

In this review, we present 4 cases that depict patients who could benefit from the addition of antiobesity pharmacotherapy to a comprehensive treatment plan that includes diet, physical activity, and behavioral modification.

CASE 1 Young obese woman is unable to lose weight

A 27-year-old woman with obesity (BMI 33 kg/m²), hyperlipidemia, and migraine headaches, presents for weight management. Despite a calorie-reduced diet and 200 minutes per week of exercise for the past 6 months, she has been unable to lose weight. The only medications she is taking are oral contraceptive pills and sumatriptan, as needed. She suffers from migraines 3 times a month and has no anxiety. Laboratory test results are normal with the exception of an elevated low-density lipoprotein (LDL) level.

Which medication is an appropriate next step for this patient?

Ask 2 important questions

When considering an antiobesity agent for any patient, there are 2 important questions to ask:

- Are there contraindications, drug-drug interactions, or undesirable adverse effects associated with this medication that could be problematic for the patient?
- Can this medication improve other symptoms or conditions the patient has?

In addition, see “Before prescribing antiobesity medication . . .” on page 45.

Phentermine/topiramate ER

Phentermine/topiramate ER is a good first choice for this young patient with class I (BMI 30–34.9 kg/m²) obesity and migraines, as she can likely tolerate a stimulant and her migraines might improve with topiramate. Before starting the medication, ask about insomnia and nephrolithiasis in addition to anxiety and other contraindications (ie, glaucoma, hyperthyroidism, recent monoamine oxidase inhibitor use, or a known hypersensitivity or idiosyncrasy to sympathomimetic amines).23 The most common adverse events reported in phase III trials were dry mouth, paresthesia, and constipation.24–26

Not for pregnant women. Women of childbearing age must have a negative pregnancy test before starting phentermine/topiramate ER and every month while taking the medication. The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) to inform prescribers and patients about the increased risk of congenital malformation, specifically orofacial clefts, in infants exposed to topiramate during the first trimester of pregnancy.42 REMS focuses on the importance of pregnancy prevention, the consistent use of birth control, and the need to discontinue phentermine/topiramate ER immediately if pregnancy occurs.

Flexible dosing. Phentermine/topiramate ER is available in 4 dosages: phentermine 3.75 mg/topiramate 23 mg ER; phentermine 7.5 mg/topiramate 46 mg ER; phentermine 11.25 mg/topiramate 69 mg ER; and phentermine 15 mg/topiramate 92 mg ER. Gradual dose escalation minimizes risks and adverse events.23

Monitor patients frequently to evaluate for adverse effects and ensure adherence to diet, exercise, and lifestyle modifications. If weight loss is slower or less robust than expected, check for dietary indiscretion, as medications have limited efficacy without appropriate behavioral changes.
Discontinue phentermine/topiramate ER if the patient does not achieve 5% weight loss after 12 weeks on the maximum dose, as it is unlikely that she will achieve and sustain clinically meaningful weight loss with continued treatment. In this case, consider another agent with a different mechanism of action. Any of the other antiobesity medications could be appropriate for this patient.

**CASE 2** Overweight woman with comorbidities

A 52-year-old overweight woman (BMI 29 kg/m²) with type 2 diabetes, hyperlipidemia, osteoarthritis, and glaucoma has recently hit a plateau with her weight loss. She lost 45 lb secondary to diet and exercise, but hasn’t been able to lose any more. She also struggles with constant hunger. Her medications include metformin 1,000 mg twice per day, atorvastatin 10 mg/d, and occasional acetaminophen/oxycodeone for knee pain until she undergoes a left knee replacement. Laboratory values are normal except for a hemoglobin A₁c of 7.2%.

The patient is afraid of needles and cannot tolerate stimulants due to anxiety. Which medication is an appropriate next step for this patient?

**What are good choices for this patient?**

Lorcaserin is a good choice for this patient who is overweight and has several weight-related comorbidities. She has worked hard to lose a significant number of pounds and is now at high risk of regaining them. That’s because her appetite has increased with her new exercise regimen, but her energy expenditure has decreased secondary to metabolic adaptation.

**Narrowing the field.** Naltrexone SR/buproprion SR cannot be used because of her opioid use. Phentermine/topiramate ER is contraindicated for patients with glaucoma, and liraglutide 3 mg is not appropriate given the patient’s fear of needles.

She could try orlistat, especially if she struggles with constipation, but the gastrointestinal adverse effects are difficult for many patients to tolerate. While not an antiobesity medication, a sodium-glucose co-transporter 2 (SGLT2) inhibitor could be prescribed for her diabetes and also may promote weight loss.

**An appealing choice.** The glucose-lowering effect of lorcaserin could provide an added benefit for the patient. The BLOOMDM (Behavioral modification and lorcaserin for overweight and obesity management in diabetes mellitus) study reported a mean reduction in hemoglobin A₁c of 0.9% in the treatment group compared with a 0.4% reduction in the placebo group, and the effect of lorcaserin on A₁c appeared to be independent of weight loss.

**Mechanism of action: Cause for concern?** Although lorcaserin selectively binds to serotonin 5-HT2C receptors, the theoretical risk of cardiac valvulopathy was evaluated in phase III studies, as fenfluramine, a 5-HT2B-receptor agonist, was withdrawn from the US market in 1997 for this reason.

Before prescribing antiobesity medication . . .

Have a frank discussion with the patient and be sure to cover the following points:

- The rationale for pharmacologic treatment is to counteract adaptive physiologic responses, which increase appetite and reduce energy expenditure, in response to diet-induced weight loss.
- Antiobesity medication is only one component of a comprehensive treatment plan, which also includes diet, physical activity, and behavior modification.
- Antiobesity agents are intended for long-term use, as obesity is a chronic disease. If/when you stop the medication, there may be some weight regain, similar to an increase in blood pressure after discontinuing an antihypertensive agent.
- Because antiobesity medications improve many parameters including glucose/hemoglobin A₁c, lipids, blood pressure, and waist circumference, it is possible that the addition of one antiobesity medication can reduce, or even eliminate, the need for several other medications.

Remember that many patients who present for obesity management have experienced weight bias. It is important not to be judgmental, but rather explain why obesity is a chronic disease. If patients understand the physiology of their condition, they will understand that their limited success with weight loss in the past is not just a matter of willpower. Lifestyle change and weight loss are extremely difficult, so it is important to provide encouragement and support for ongoing behavioral modification.
Obesity: When to consider medication

and lorcaserin for overweight and obesity management) and BLOSSOM (Behavioral modification and lorcaserin second study for obesity management) studies found that lorcaserin did not increase the incidence of FDA-defined cardiac valvulopathy.28,29

**Formulations/adverse effects.** Lorcaserin is available in 2 formulations: 10-mg tablets, which are taken twice daily, or 20-mg XR tablets, which are taken once daily. Both are generally well tolerated.27,45 The most common adverse event reported in phase III trials was headache.26,30,43 Discontinue lorcaserin if the patient does not lose 5% of her initial weight after 12 weeks, as weight loss at this stage is a good predictor of longer-term success.46

**Some patients don’t respond.** Interestingly, a subset of patients do not respond to lorcaserin. The most likely explanation for different responses to the medication is that there are many causes of obesity, only some of which respond to 5-HT2C agonism. Currently, we do not perform pharmacogenomics testing before prescribing lorcaserin, but perhaps an inexpensive test to identify responders will be available in the future.

**CASE 3 A preoccupation with food**

A 38-year-old woman with obesity (BMI 42 kg/m²), obstructive sleep apnea, gastroesophageal reflux disease, and depression is eager to get better control over her weight. Her medications include lansoprazole 30 mg/d and a multivitamin. She reports constantly thinking about food and not being able to control her impulses to buy large quantities of unhealthy snacks. She is so preoccupied by thoughts of food that she has difficulty concentrating at work.

The patient smokes a quarter of a pack of cigarettes daily, but she is ready to quit. She views bariatric surgery as a “last resort” and has no anxiety, pain, or history of seizures. Which medication is appropriate for this patient?

**Discuss all options**

This patient with class III obesity (BMI ≥40 kg/m²) is eligible for bariatric surgery; however, she is not interested in pursuing it at this time. It is important to discuss all of her options before deciding on a treatment plan. For patients like this, who would benefit from more than modest weight loss, consider a multidisciplinary approach including lifestyle modifications, pharmacotherapy, devices (eg, an intragastric balloon), and/or surgery. You would need to make clear to the patient that she may still be eligible for insurance coverage for surgery if she changes her mind after pursuing other treatments as long as her BMI remains ≥35 kg/m² with obesity-related comorbidities.

**Naltrexone SR/bupropion SR** is a good choice for this patient because she describes debilitating cravings and addictive behavior surrounding food. Patients taking naltrexone SR/bupropion SR in the Contrave Obesity Research (COR)-I and COR-II phase III trials experienced a reduced frequency of food cravings, reduced difficulty in resisting food cravings, and an increased ability to control eating compared with those assigned to placebo.32,33

**Added benefits.** Bupropion also could help this patient quit smoking and improve her mood, as it is FDA-approved for smoking cessation and depression. She denies anxiety and seizures, so bupropion is not contraindicated. Even if a patient denies a history of seizure, ask about any conditions that predispose to seizures, such as anorexia nervosa or bulimia or the abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.

**Opioid use.** Although the patient denies pain, ask about potential opioid use, as naltrexone is an opioid receptor antagonist. Patients should be informed that opioids may be ineffective if they are required unexpectedly (eg, for trauma) and that naltrexone SR/bupropion SR should be withheld for any planned surgical procedure potentially requiring opioid use.

**Other options.** While naltrexone SR/bupropion SR is the most appropriate choice for this patient because it addresses her problematic eating behaviors while potentially improving mood and assisting with smoking cessation, phentermine/topiramate ER, lorcaserin, and liraglutide 3 mg also could be used and certainly should be tried if...
Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia syndrome type 2.

**Contraindications.** Ask patients about a history of pancreatitis before starting liraglutide 3 mg, given the possible increased risk. In addition, liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2. Thyroid C-cell tumors have been found in rodents given supratherapeutic doses of liraglutide,

For patients taking a medication that can cause hypoglycemia, such as insulin or a sulfonylurea, monitor blood sugar and consider reducing the dose of that medication when starting liraglutide.

**Administration and titration.** Liraglutide is injected subcutaneously once daily. The dose is titrated up weekly to reduce gastrointestinal symptoms.

**References**


CONTINUED ON PAGE 48


